NorthStar breaks new ground
Northstar Medical Radioisotopes hosts groundbreaking event
The CCI team is proud to be part of NorthStar’s phase two expansion. The 20,000-sqft facility will house additional production and shipping capabilities. The event was also held to celebrate the FDA’s recent approval of NorthStar’s RadioGenix System, the first and only system of it’s kind for use in the domestic production of non-uranium based molybdenum-99 (Mo-99). Mo-99 is the most widely used radioisotope in medical diagnostic imaging. Our congratulations to the NorthStar team!